<DOC>
	<DOCNO>NCT00002944</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This randomized phase III trial study two different combination chemotherapy regimens compare well work treat child low-grade astrocytomas residual tumor brain .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Progressive Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Compare event free survival result treatment carboplatin vincristine versus thioguanine , procarbazine , lomustine , vincristine child progressive brain tumor . - Estimate tumor response rate regimen chemotherapy patient . - Determine toxic effect quality life child treat regimen chemotherapy . - Investigate biological clinical factor may predict tumor response early progression ( tumor size , location , pathologic subtype , cytogenetics , proliferative index MIB-1 ( Ki67 ) ) patient . - Investigate factor contribute neuropsychological endocrine status child brain tumor treat without irradiation . OUTLINE : This randomize study . Patients stratify accord site disease , status entry , pathology . Patients randomize one two treatment arm . Patients neurofibromatosis nonrandomly assign arm II . - Arm I : Patients receive induction carboplatin vincristine 10 week follow 2 week rest . Induction follow 8 course maintenance begin day 84 induction upon hematopoietic recovery . Each course consist 4 weekly dos carboplatin 3 weekly dos vincristine ( give concurrently first 3 week carboplatin ) , follow 2 week rest . - Arm II : Patients receive oral thioguanine , procarbazine , lomustine day 0-4 , follow vincristine IV day 14 28 . Treatment continue every 6 week maximum 8 course . PROJECTED ACCRUAL : A total 280-340 patient accrue 4 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm low grade residual astrocytomas eligible residual tumor brain interpret low grade ( WHO grade I II ) following : Glial Tumors Astrocytic tumor Low grade astrocytoma ( variant : fibrillary , protoplasmic , gemistocytic ) Pilocytic astrocytoma Pleomorphic xanthoastrocytomas Subependymal giant cell astrocytoma Infantile desmoplastic astrocytoma Low grade oligodendroglial tumor Low grade oligodendroglioma Low grade mixed glioma Oligoastrocytoma Neuronal Tumors Ganglioglioma ( exclude tumor anaplastic astrocytic component ) Infantile desmoplastic ganglioglioma Chiasmatichypothalamic tumor without histologic confirmation All following diagnostic test ( radiological clinical evidence progression , surgery , confirmatory MRI ) must carry within 6 week enrollment study Progressive disease follow surgical excision base clear radiological clinical evidence progression , incomplete excision ( le 95 % great 1.5 cm2 ) necessity begin treatment risk neurologic impairment progression Chiasmatic lesion contiguous extension tumor region visual pathway demonstrate contrast MRI eligible study without histopathological confirmation Patients neurofibromatosis radiographic diagnosis chiasmatichypothalamic tumor eligible study , without require biopsy confirmation tumor histology , unless tumor progression document radiographically No intrinsic brain stem tumor pons isolate optic nerve tumor without definitive involvement optic chiasm PATIENT CHARACTERISTICS : Age : Under 10 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,000/mm^3 ( arm II ) Platelet count great 100,000/mm^3 ( arm II ) Hepatic : Not specify Renal : Creatinine le 1.5 time upper limit normal age OR Creatinine clearance radioisotope GFR great 70 mL/min equivalent GFR determine institutional normal range PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy tumor Endocrine therapy : Prior corticosteroid therapy allow Radiotherapy : No prior radiotherapy tumor Surgery : See Disease characteristic Other : Prior diuretic therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood visual pathway glioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>childhood low-grade cerebellar astrocytoma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
</DOC>